Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3105674
Max Phase: Preclinical
Molecular Formula: C26H22N2O4S2
Molecular Weight: 490.61
Molecule Type: Small molecule
Associated Items:
ID: ALA3105674
Max Phase: Preclinical
Molecular Formula: C26H22N2O4S2
Molecular Weight: 490.61
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(C(=O)c3ccccc3)s2)cc1
Standard InChI: InChI=1S/C26H22N2O4S2/c1-2-34(31,32)21-15-13-18(14-16-21)17-22(29)27-26-28-23(19-9-5-3-6-10-19)25(33-26)24(30)20-11-7-4-8-12-20/h3-16H,2,17H2,1H3,(H,27,28,29)
Standard InChI Key: MDMLFHGEDDZHNU-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 490.61 | Molecular Weight (Monoisotopic): 490.1021 | AlogP: 5.02 | #Rotatable Bonds: 8 |
Polar Surface Area: 93.20 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 7.81 | CX Basic pKa: | CX LogP: 5.36 | CX LogD: 5.23 |
Aromatic Rings: 4 | Heavy Atoms: 34 | QED Weighted: 0.35 | Np Likeness Score: -1.74 |
1. Wang Y, Cai W, Zhang G, Yang T, Liu Q, Cheng Y, Zhou L, Ma Y, Cheng Z, Lu S, Zhao YG, Zhang W, Xiang Z, Wang S, Yang L, Wu Q, Orband-Miller LA, Xu Y, Zhang J, Gao R, Huxdorf M, Xiang JN, Zhong Z, Elliott JD, Leung S, Lin X.. (2014) Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors., 22 (2): [PMID:24388993] [10.1016/j.bmc.2013.12.021] |
2. Gege C, Schlüter T, Hoffmann T.. (2014) Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt., 24 (22): [PMID:25305688] [10.1016/j.bmcl.2014.09.053] |
3. Fauber BP, Magnuson S.. (2014) Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc)., 57 (14): [PMID:24502334] [10.1021/jm401901d] |
4. Wang Y, Cai W, Tang T, Liu Q, Yang T, Yang L, Ma Y, Zhang G, Huang Y, Song X, Orband-Miller LA, Wu Q, Zhou L, Xiang Z, Xiang JN, Leung S, Shao L, Lin X, Lobera M, Ren F.. (2018) From RORγt Agonist to Two Types of RORγt Inverse Agonists., 9 (2): [PMID:29456799] [10.1021/acsmedchemlett.7b00476] |
Source(1):